Becton Dickinson Management
Management criteria checks 4/4
Becton Dickinson's CEO is Tom Polen, appointed in Apr 2017, has a tenure of 7.08 years. total yearly compensation is $17.31M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth $13.82M. The average tenure of the management team and the board of directors is 2.5 years and 6.5 years respectively.
Key information
Tom Polen
Chief executive officer
US$17.3m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.5yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)
Mar 23
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Feb 29Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings
Feb 08Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 03These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Feb 01Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Jan 22Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 30Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24
Nov 13Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's
Nov 12Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price
Nov 06With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case
Oct 05Becton, Dickinson Stock Is A Hold, Here's Why
Oct 04Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers
Aug 30We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Aug 13Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Jul 28Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching
Jun 22Becton, Dickinson and Company: Still Not Very Healthy
Jun 20Becton, Dickinson: Business Should Beat H2 2023 Expectations
Jun 08These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Apr 22Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?
Mar 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Mar 05Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use
Feb 21Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test
Feb 08Becton, Dickinson Q1 2023 Earnings Preview
Feb 01Becton, Dickinson declares $0.91 dividend
Jan 24We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Jan 09CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod
Jan 09Becton, Dickinson: A Quality Defensive Pick For 2023
Dec 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Dec 01Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91
Nov 13Becton, Dickinson Q4 2022 Earnings Preview
Nov 09Becton, Dickinson, Biocorp team up for traceability of injectable drugs
Oct 18Becton, Dickinson: Buy In Now While You Can
Oct 12Does Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?
Oct 05BD, Certest Biotec launch monkeypox test
Sep 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | US$17m | US$1m | US$1b |
| Jun 30 2023 | n/a | n/a | US$2b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | n/a | n/a | US$1b |
| Sep 30 2022 | US$17m | US$1m | US$2b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$1b |
| Dec 31 2021 | n/a | n/a | US$1b |
| Sep 30 2021 | US$14m | US$1m | US$2b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | n/a | n/a | US$2b |
| Sep 30 2020 | US$12m | US$952k | US$245m |
| Jun 30 2020 | n/a | n/a | US$786m |
| Mar 31 2020 | n/a | n/a | US$923m |
| Dec 31 2019 | n/a | n/a | US$760m |
| Sep 30 2019 | US$6m | US$900k | US$1b |
| Jun 30 2019 | n/a | n/a | US$784m |
| Mar 31 2019 | n/a | n/a | US$926m |
| Dec 31 2018 | n/a | n/a | US$894m |
| Sep 30 2018 | US$6m | US$850k | US$159m |
| Jun 30 2018 | n/a | n/a | US$621m |
| Mar 31 2018 | n/a | n/a | -US$99m |
| Dec 31 2017 | n/a | n/a | US$294m |
| Sep 30 2017 | US$4m | US$761k | US$1b |
Compensation vs Market: Tom's total compensation ($USD17.31M) is about average for companies of similar size in the US market ($USD13.56M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom Polen (50 yo)
7.1yrs
Tenure
US$17,309,938
Compensation
Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.1yrs | US$17.31m | 0.020% $ 13.8m | |
| Executive VP & CFO | 2.7yrs | US$5.21m | 0.0014% $ 962.4k | |
| Executive VP & Chief People Officer | 2.1yrs | US$5.89m | 0.0057% $ 3.8m | |
| Executive VP & President of Life Sciences Segment | 3.3yrs | US$3.35m | 0.0043% $ 2.9m | |
| Executive VP & President of Medical segment | 1.7yrs | US$3.65m | 0.0025% $ 1.7m | |
| Senior VP | 4.6yrs | no data | 0.00083% $ 562.5k | |
| Executive VP & Chief Technology Officer | 3.1yrs | no data | no data | |
| Senior VP | 2.5yrs | no data | no data | |
| Executive VP of Technology & Global Services and Chief Information Officer | 2.3yrs | no data | no data | |
| Head of Investor Relations | less than a year | no data | no data | |
| Executive VP & General Counsel | 1.3yrs | no data | 0.0017% $ 1.2m | |
| Senior VP | no data | no data | no data |
2.5yrs
Average Tenure
53yo
Average Age
Experienced Management: BDX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$17.31m | 0.020% $ 13.8m | |
| Senior VP | 2.5yrs | no data | no data | |
| Co-Chair of Scientific Advisory Board | 3yrs | no data | no data | |
| Independent Director | 7.7yrs | US$362.77k | 0.0028% $ 1.9m | |
| Independent Director | 7.3yrs | US$332.78k | 0.020% $ 13.9m | |
| Independent Director | 5.8yrs | US$357.78k | 0.0019% $ 1.3m | |
| Independent Director | 13.8yrs | US$362.78k | 0.0074% $ 5.0m | |
| Lead Independent Director | 21.7yrs | US$372.78k | 0.012% $ 8.3m | |
| Independent Director | 11.3yrs | US$348.58k | 0.0046% $ 3.1m | |
| Independent Director | 2.3yrs | US$332.78k | 0.00087% $ 589.7k | |
| Member of Scientific Advisory Board & Independent Director | 17.5yrs | US$340.15k | 0.0079% $ 5.3m | |
| Independent Director | 2.6yrs | US$337.78k | 0.00099% $ 671.0k |
6.5yrs
Average Tenure
61yo
Average Age
Experienced Board: BDX's board of directors are considered experienced (6.5 years average tenure).